Carbidopa

Kyowa Kirin Announces NOURIANZ™ (Istradefylline) Now Available in the U.S. for Treatment of Parkinson’s Disease “Off” Episodes

Monday, October 14, 2019 - 11:47pm

Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.

Key Points: 
  • Kyowa Kirin, Inc. (Kyowa Kirin), an affiliate of Kyowa Kirin Co., Ltd. (TSE: 4151), announced today that NOURIANZ (istradefylline) is now available in the U.S. as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • To help patients with questions about access to NOURIANZ, Kyowa Kirin offers the Kyowa Kirin Cares program.
  • NOURIANZ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing off episodes.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference

Wednesday, September 25, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the 2019 Cantor Global Healthcare Conference on Friday, October 4 at 11:15AM ET.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda to Present Data at the International Congress of Parkinson’s Disease and Movement Disorders

Wednesday, September 18, 2019 - 12:00pm

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.

Key Points: 
  • Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will present data at the International Congress of Parkinsons Disease and Movement Disorders, taking place September 22-26, 2019 in Nice, France.
  • Fox Foundation Industry Advisory Board and contributed to the design of and provided funding for the Financial and Social Impact of Parkinsons Disease Survey.
  • Results of the survey were also presented at the 5th World Parkinson Congress in June 2019.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.

Kyowa Kirin Announces FDA Approval of NOURIANZ™ (istradefylline) for Use in Parkinson’s Disease

Wednesday, August 28, 2019 - 2:34pm

Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.

Key Points: 
  • Kyowa Kirin Co., Ltd., (Kyowa Kirin, TYO: 4151) announces today that the U.S. Food and Drug Administration (FDA) has granted approval for NOURIANZ (istradefylline) for use as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinsons disease (PD) experiencing OFF episodes.
  • We are proud that NOURIANZ is now ready to help adult patients with Parkinsons disease in the US, said Tomohiro Sudo, Head of Global Product Management Office of Kyowa Kirin.
  • We are grateful for the FDA approval and for the many dedicated scientists and patients whose participation in our research programs has resulted in a new treatment option for Parkinson's disease.
  • Parkinsons disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement and postural instability.

Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders

Tuesday, June 25, 2019 - 12:00pm

JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.

Key Points: 
  • JERUSALEM, June 25, 2019 /PRNewswire/ ---Intec Pharma Ltd.(NASDAQ: NTEC) ("Intec" or "the Company") today announces that results from an earlier Phase 2 clinical study of the Accordion Pill-Carbidopa/Levodopa (AP-CD/LD) in Parkinson's disease (PD) patients were published in the peer-reviewed journal, Parkinsonism and Related Disorders.
  • The article presents results from cohorts 1-4 out of the 6 cohorts of PD patients who participated in the study.
  • Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.
  • Modi, Clinical pharmacokinetics of IPX066: evaluation of dose proportionality and effect of food in healthy volunteers, Clin.

Acorda Therapeutics to Present at Jefferies 2019 Healthcare Conference

Thursday, May 23, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Wednesday, June 5 at 8:00AM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in patients with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill™ Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients

Tuesday, April 30, 2019 - 12:00pm

"We are excited to announce that the last patient's last visit has taken place as it is an important milestone in the development of our Accordion Pill platform.

Key Points: 
  • "We are excited to announce that the last patient's last visit has taken place as it is an important milestone in the development of our Accordion Pill platform.
  • Completion of the ACCORDANCE study brings us closer to potentially providing an enhanced baseline levodopa treatment to advanced PD patients," stated R. Michael Gendreau, M.D., Ph.D., Chief Medical Officer of Intec Pharma.
  • The Phase 3 ACCORDANCE clinical trial of AP-CD/LD is a multi-center, global, randomized, double-blind, double-dummy, active-controlled, parallel-group study in adult subjects with advanced PD.
  • The Accordion Pill Carbidopa/Levodopa (AP-CD/LD) is a gastric-retentive drug delivery system containing carbidopa and levodopa in both immediate and extended-release modes.

Acorda to Present at Oppenheimer’s 29th Annual Healthcare Conference

Wednesday, March 6, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Oppenheimer & Co.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Andrew Hindman, Acordas Chief Business Officer, will present at the Oppenheimer & Co.
  • Annual Healthcare Conference on Tuesday, March 19 at 1:35 p.m. EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.

Acorda Therapeutics Announces Commercial Launch of INBRIJA™ (levodopa inhalation powder)

Thursday, February 28, 2019 - 9:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR ) today announced that INBRIJA is now available by prescription in the United States.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR ) today announced that INBRIJA is now available by prescription in the United States.
  • Acorda Therapeutics develops therapies to restore function and improve the lives of people with neurological disorders.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • INBRIJA utilizes Acordas innovative ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation.

Acorda Therapeutics to Present at Cowen Annual Health Care Conference

Tuesday, February 26, 2019 - 12:00pm

Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST.

Key Points: 
  • Acorda Therapeutics, Inc. (NASDAQ: ACOR) announced that Ron Cohen, M.D., Acordas President and Chief Executive Officer, will present at the Cowen and Company Global Health Care Conference on Monday, March 11 at 1:30PM EST.
  • INBRIJA (levodopa inhalation powder) is approved for intermittent treatment of OFF episodes in adults with Parkinsons disease treated with carbidopa/levodopa.
  • Acorda also markets the branded AMPYRA (dalfampridine) Extended Release Tablets, 10 mg.
  • All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking.